The caveolar nitric oxide synthase/arginine regeneration system for NO production in endothelial cells.
about
L-citrulline provides a novel strategy for treating chronic pulmonary hypertension in newborn infantsMechanical dynamics in live cells and fluorescence-based force/tension sensorsArgininosuccinate synthetase is a functional target for a snake venom anti-hypertensive peptide: role in arginine and nitric oxide production.Vascular dysfunction in retinopathy-an emerging role for arginaseBothrops jararaca peptide with anti-hypertensive action normalizes endothelium dysfunction involved in physiopathology of preeclampsia.l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbitsNitric oxide and cGMP mediate alpha1D-adrenergic receptor-Stimulated protein secretion and p42/p44 MAPK activation in rat lacrimal gland.Molecular physiopathogenetic mechanisms and development of new potential therapeutic strategies in persistent pulmonary hypertension of the newbornEndothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetesEndothelial arginase II and atherosclerosis.A preliminary study on protective effect of L-citrulline against ischemia-reperfusion induced gastric mucosal lesions in ratRequirement of argininosuccinate lyase for systemic nitric oxide production.Prolonged hypoxia augments L-citrulline transport by system A in the newborn piglet pulmonary circulation.Chronic hypoxia decreases arterial and venous compliance in isolated perfused rat lungs: an effect that is reversed by exogenous L-arginine.Endothelial nitric-oxide synthase activation generates an inducible nitric-oxide synthase-like output of nitric oxide in inflamed endothelium.Impaired nitric oxide production in children with MELAS syndrome and the effect of arginine and citrulline supplementation.Nitric oxide deficiency in pulmonary hypertension: Pathobiology and implications for therapy.Arginase and vascular aging.Development of novel arginase inhibitors for therapy of endothelial dysfunctionSodium-coupled neutral amino acid transporter 1 (SNAT1) modulates L-citrulline transport and nitric oxide (NO) signaling in piglet pulmonary arterial endothelial cells.Nitric oxide and the cardiovascular system.Inflammation, vasospasm, and brain injury after subarachnoid hemorrhage.Combined L-citrulline and glutathione supplementation increases the concentration of markers indicative of nitric oxide synthesis.Effects of L-citrulline oral supplementation on polymorphonuclear neutrophils oxidative burst and nitric oxide production after exercise.Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells.The subcellular compartmentalization of arginine metabolizing enzymes and their role in endothelial dysfunction.L-Citrulline ameliorates chronic hypoxia-induced pulmonary hypertension in newborn piglets.An NADPH sensor protein (HSCARG) down-regulates nitric oxide synthesis by association with argininosuccinate synthetase and is essential for epithelial cell viability.Pulmonary hypertension in the premature infant population: Analysis of echocardiographic findings and biomarkers.Protective effect of L-citrulline against acute gastric mucosal lesions induced by ischemia-reperfusion in rats.Altered angiogenesis in caveolin-1 gene-deficient mice is restored by ablation of endothelial nitric oxide synthase.Systemic L-citrulline prevents cerebral vasospasm in haptoglobin 2-2 transgenic mice after subarachnoid hemorrhage.
P2860
Q26829856-1AA6D3C3-4589-4E88-8F55-07846CAB0C4AQ28834419-6CE8867B-9C12-4625-BE40-88B3FF8E097FQ29144136-E2B86D0F-B242-41CF-946C-5DD1EBA0C1ABQ33625727-FCA98E0B-AC93-4184-BCAF-00932A784A0BQ33999976-34643A08-5281-4843-88B3-78E66258B8B4Q34016071-BB764B49-18BB-4ED0-8161-A968FAD7E23FQ34375011-0DA2628C-FE8E-4985-8C59-3B5A05F4311DQ35084278-6AB454E1-C2BC-48FA-B9E6-BF08FECA34ECQ35118818-2236F4A5-6019-4EDB-8EDD-FA1B52FC4C65Q35161493-A1D9EA54-519F-4474-B199-E46B8F4F03CFQ35732576-F337455E-993E-4B12-8C5C-7A79E5707BDDQ35948795-ACD90755-FE01-45F3-84AC-F10C4AD3A61DQ36104442-B451F31E-7BE6-4B06-90FB-C69386B48021Q36528050-7D5D28B0-E0B5-4B98-B8C9-737A2B4E812BQ36596268-C777DBA6-7FD8-4F59-86E6-CC90F579572CQ36759443-48471D4E-E04F-4E8B-8E49-35EB78362A30Q36810804-15764857-B281-492F-83BF-F02B35D67B34Q36977086-5CE18B18-8BDA-4428-B938-F724FDF63801Q37176702-4943147C-06CA-46D9-8711-C0ECCCF90462Q37484397-55485A5E-B8E0-41A1-AADE-15339738B725Q38423876-849C8F5F-F16E-4CAB-BC85-8C5218A7C6E2Q41958830-2E6A4E63-1592-450C-9FAC-4C000DB8E77AQ42424448-C0F133D2-B702-416F-BDE3-FEA029E7E2E0Q42456591-BCBF08D0-8C3A-46BA-BFB2-FC01353B382DQ42457342-F7EAA296-8481-4E56-A3CD-1B547E1FD8C7Q43101543-C4F51055-F59A-4585-852A-42700336814AQ45925606-65AAB644-7734-4D2C-B9BB-5C8CB64ABE3AQ46762019-9546CCF8-91F4-4905-A922-11975EFEF737Q47701959-4AC7884C-5205-401A-A2D8-2971D4439426Q48260202-9B9E8BC0-951C-477D-B052-DF0D4619EA2BQ49734562-52C3282E-DF4F-4E19-95C0-F261CD3D087FQ54349093-87E48AFD-20A9-4CCA-8F39-7C1ECAC8D66A
P2860
The caveolar nitric oxide synthase/arginine regeneration system for NO production in endothelial cells.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@ast
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@en
type
label
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@ast
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@en
prefLabel
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@ast
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@en
P2093
P356
P1476
The caveolar nitric oxide synt ...... oduction in endothelial cells.
@en
P2093
Bonnie L Goodwin
Brenda R Flam
Duane C Eichler
Larry P Solomonson
Laura C Pendleton
P304
P356
10.1242/JEB.00361
P577
2003-06-01T00:00:00Z